15 octubre 2013

Zeltia SA : 7 New studies with Yondelis® in Ovarian Cancer presented at the 18th Meeting of the European Society of Gynaecological Oncology (ESGO) .

10/14/2013 | 02:21pm US/Eastern .

ZELTIA NEWS: 7 New studies with Yondelis® in Ovarian Cancer presented at the 18th Meeting of the European Society of Gynaecological Oncology (ESGO) - Yondelis® (trabectedin) given prior to subsequent platinum rechallenge may prolong the platinum free- interval and reverse or reduce tumour cell resistance to platinum, leading to enhanced outcomes and longer survival. - Over 2,500 gynaecological oncologists and researchers, will attend ESGO's 18th International Meeting to be held in Liverpool, UK between the 19th to 22nd October 2013.

...